- Home
- CSTL vs BLDP Comparison
CSTL vs BLDP Comparison
Compare CSTL & BLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- BLDP
- Stock Information
- Founded
- CSTL 2007
- BLDP 1979
- Country
- CSTL United States
- BLDP Canada
- Employees
- CSTL N/A
- BLDP N/A
- Industry
- CSTL Medical Specialities
- BLDP Industrial Machinery/Components
- Sector
- CSTL Health Care
- BLDP Energy
- Exchange
- CSTL Nasdaq
- BLDP Nasdaq
- Market Cap
- CSTL 697.9M
- BLDP 622.2M
- IPO Year
- CSTL 2019
- BLDP 1995
- Fundamental
- Price
- CSTL $22.75
- BLDP $3.64
- Analyst Decision
- CSTL Strong Buy
- BLDP Sell
- Analyst Count
- CSTL 6
- BLDP 8
- Target Price
- CSTL $37.67
- BLDP $1.50
- AVG Volume (30 Days)
- CSTL 348.6K
- BLDP 9.5M
- Earning Date
- CSTL 11-03-2025
- BLDP 11-04-2025
- Dividend Yield
- CSTL N/A
- BLDP N/A
- EPS Growth
- CSTL N/A
- BLDP N/A
- EPS
- CSTL N/A
- BLDP N/A
- Revenue
- CSTL $346,269,000.00
- BLDP $72,507,000.00
- Revenue This Year
- CSTL N/A
- BLDP $28.78
- Revenue Next Year
- CSTL N/A
- BLDP $20.81
- P/E Ratio
- CSTL N/A
- BLDP N/A
- Revenue Growth
- CSTL 20.40
- BLDP N/A
- 52 Week Low
- CSTL $14.59
- BLDP $1.00
- 52 Week High
- CSTL $35.84
- BLDP $3.85
- Technical
- Relative Strength Index (RSI)
- CSTL 52.78
- BLDP 80.60
- Support Level
- CSTL $22.28
- BLDP $2.64
- Resistance Level
- CSTL $23.71
- BLDP $3.85
- Average True Range (ATR)
- CSTL 1.05
- BLDP 0.24
- MACD
- CSTL -0.12
- BLDP 0.08
- Stochastic Oscillator
- CSTL 35.90
- BLDP 84.90
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About BLDP Ballard Power Systems Inc.
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from Poland followed by United States, United Kingdom, and other countries.